Limits...
Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.

Refaat B, Ashshi AM, El-Shemi AG, Azhar E - Mediators Inflamm. (2015)

Bottom Line: The currently used markers to monitor the response to treatment are based on viral kinetics and their performance in the prediction of treatment outcome is moderate and does not combine accuracy and their values have several limitations.The importance of activins and follistatin in the regulation of immune system, liver biology, and pathology has recently emerged.This review appraises the up-to-date knowledge regarding the role of activins and follistatin in liver biology and immune system and their role in the pathophysiology of CHC.

View Article: PubMed Central - PubMed

Affiliation: Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al-'Abdiyah Campus, P. O. Box 7607, Makkah, Saudi Arabia.

ABSTRACT
Pegylated-interferon-α based therapy for the treatment of chronic hepatitis C (CHC) is considered suboptimal as not all patients respond to the treatment and it is associated with several side effects that could lead to dose reduction and/or termination of therapy. The currently used markers to monitor the response to treatment are based on viral kinetics and their performance in the prediction of treatment outcome is moderate and does not combine accuracy and their values have several limitations. Hence, the development of new sensitive and specific predictor markers could provide a useful tool for the clinicians and healthcare providers, especially in the new era of interferon-free therapy, for the classification of patients according to their response to the standard therapy and only subscribing the novel directly acting antiviral drugs to those who are anticipated not to respond to the conventional therapy and/or have absolute contraindications for its use. The importance of activins and follistatin in the regulation of immune system, liver biology, and pathology has recently emerged. This review appraises the up-to-date knowledge regarding the role of activins and follistatin in liver biology and immune system and their role in the pathophysiology of CHC.

No MeSH data available.


Related in: MedlinePlus

The production of activin-A and follistatin by normal and abnormal hepatocyte. Activin-A and follistatin regulate hepatocyte regeneration in healthy liver. Pathological increase of both activin-A and follistatin by the hepatocyte is associated with several liver diseases including fibrosis, cirrhosis, and hepatocellular carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4417604&req=5

fig3: The production of activin-A and follistatin by normal and abnormal hepatocyte. Activin-A and follistatin regulate hepatocyte regeneration in healthy liver. Pathological increase of both activin-A and follistatin by the hepatocyte is associated with several liver diseases including fibrosis, cirrhosis, and hepatocellular carcinoma.

Mentions: Liver inflammation and fibrosis are closely linked and a number of observations indicate an important role for activins in these processes (Figure 3). Activins βA-, βC-, and βE-subunit expression levels were found to increase during carbon tetrachloride (CCl4) induced fibrosis in rat livers and have been implicated in destruction of hepatocytes and elevated extracellular matrix production [82, 83, 120].


Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.

Refaat B, Ashshi AM, El-Shemi AG, Azhar E - Mediators Inflamm. (2015)

The production of activin-A and follistatin by normal and abnormal hepatocyte. Activin-A and follistatin regulate hepatocyte regeneration in healthy liver. Pathological increase of both activin-A and follistatin by the hepatocyte is associated with several liver diseases including fibrosis, cirrhosis, and hepatocellular carcinoma.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4417604&req=5

fig3: The production of activin-A and follistatin by normal and abnormal hepatocyte. Activin-A and follistatin regulate hepatocyte regeneration in healthy liver. Pathological increase of both activin-A and follistatin by the hepatocyte is associated with several liver diseases including fibrosis, cirrhosis, and hepatocellular carcinoma.
Mentions: Liver inflammation and fibrosis are closely linked and a number of observations indicate an important role for activins in these processes (Figure 3). Activins βA-, βC-, and βE-subunit expression levels were found to increase during carbon tetrachloride (CCl4) induced fibrosis in rat livers and have been implicated in destruction of hepatocytes and elevated extracellular matrix production [82, 83, 120].

Bottom Line: The currently used markers to monitor the response to treatment are based on viral kinetics and their performance in the prediction of treatment outcome is moderate and does not combine accuracy and their values have several limitations.The importance of activins and follistatin in the regulation of immune system, liver biology, and pathology has recently emerged.This review appraises the up-to-date knowledge regarding the role of activins and follistatin in liver biology and immune system and their role in the pathophysiology of CHC.

View Article: PubMed Central - PubMed

Affiliation: Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al-'Abdiyah Campus, P. O. Box 7607, Makkah, Saudi Arabia.

ABSTRACT
Pegylated-interferon-α based therapy for the treatment of chronic hepatitis C (CHC) is considered suboptimal as not all patients respond to the treatment and it is associated with several side effects that could lead to dose reduction and/or termination of therapy. The currently used markers to monitor the response to treatment are based on viral kinetics and their performance in the prediction of treatment outcome is moderate and does not combine accuracy and their values have several limitations. Hence, the development of new sensitive and specific predictor markers could provide a useful tool for the clinicians and healthcare providers, especially in the new era of interferon-free therapy, for the classification of patients according to their response to the standard therapy and only subscribing the novel directly acting antiviral drugs to those who are anticipated not to respond to the conventional therapy and/or have absolute contraindications for its use. The importance of activins and follistatin in the regulation of immune system, liver biology, and pathology has recently emerged. This review appraises the up-to-date knowledge regarding the role of activins and follistatin in liver biology and immune system and their role in the pathophysiology of CHC.

No MeSH data available.


Related in: MedlinePlus